Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy is a phase 2/3 interventional study registered as NCT06780670, led by Novartis Pharmaceuticals, and recruiting when checked on 2026-09-11. Official title: PSMAcTION: A Phase II/III, Open-label, International, Multicenter, Randomised Study of AAA817 Versus Standard of Care in the Treatment of Adult Participants With PSMA Positive Metastatic Castration-resistant Prostate Cancer Who Progressed on or After [177Lu]Lu-PSMA Targeted Therapy. Planned enrolment is 443 participants (estimated). The study started in 2025-02-27 and primary completion is expected in 2028-06-27. No results have been posted on ClinicalTrials.gov.